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Mitral StenosisAmir-Ali Fassa, MD,* Dominique Himbert, MD,* Eric Brochet, MD,* Jean-Pol Depoix, MD,y
Adrian P. Cheong, MD,* Soleiman Alkhoder, MD,z Patrick Nataf, MD,z Alec Vahanian, MD*
Paris, FranceA 72-year-old woman, with prior aortic valve
replacement and tricuspid annuloplasty, was
referred for heart failure. Echocardiography showed
mitral stenosis (mean gradient 12 mm Hg, area
0.8 cm2) with severe mitral annular calciﬁcation
(MAC) (Fig. 1A). Computed tomography demon-Figure 1. Severe MAC
(A) Three-dimensional transesophageal echocardiography and (B) computed tomography showing severe annular calciﬁcation.
MAC ¼ mitral annular calciﬁcation.strated a nearly circumferential distribution of the
calciﬁcation (Fig. 1B). Because of the high surgical
risk (Logistic EuroSCORE 17%, EuroSCORE II
10%, STS score 11%), severe MAC, and long-term
corticosteroid therapy for rheumatoid arthritis, theFrom the *Department of Cardiology, Bichat-Claude-Bernard Hospital,
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France; and the zDepartment of Cardiac Surgery, Bichat-Claude-
Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris
VII, Paris, France. Dr. Himbert is a proctor for Edwards Lifesciences andheart team planned transcatheter mitral valve im-
plantation (TMVI) through a transseptal (TS)
approach, which was considered as less invasive than
the transapical route. The decision was also based
on experience from our center with TS in-
terventions (1). The procedure was performedfrom the right femoral vein, under general anes-
thesia and guidance by transesophageal echocar-
diography (TEE). After TS puncture and dilation
of the atrial septum with a 14-mm balloon, an
Amplatz Extra-Stiff guidewire (Cook Medical,Medtronic; and is a consultant for Edwards Lifesciences. Dr. Nataf is a
proctor for Edwards Lifesciences. Dr. Vahanian has received speaker’s fees
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Figure 2. Transseptal Transcatheter Mitral Valve Implantation
(A) Implantation of a 26-mm SAPIEN XT valve (Online Video 1). (B and C) Perpendicular and en face views (Online Videos 2 and 3). (D) Color Doppler transesophageal
echocardiography (TEE) showingmild paravalvular regurgitation (Online Video 4). Post-implantation 3-dimensional TEE (E) (Online Video 5) and computed tomography (F).
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697Bloomington, Indiana) was positioned in the left ventricle.
A 26-mm SAPIEN XT valve (Edwards Lifesciences,
Irvine, California) was then successfully implanted within
the mitral annulus, using slow inﬂation during rapid ven-
tricular pacing (Fig. 2, Online Videos 1, 2, 3, 4, and 5). TEE
showed mild paravalvular regurgitation and a mean gradient
of 4 mm Hg. Hospital stay was uneventful, and the patient
was discharged 7 days after the intervention.
TMVI has only been described through a transapical or
an open left atrial approach (2–4). This ﬁrst report suggests
that the TS route may represent a less invasive approach for
this novel technique in selected patients with severely
calciﬁed mitral stenosis at high risk for surgery. The decision
to perform this intervention should be on the basis of a
critical assessment by the heart team.
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APPENDIX
For accompanying videos, please see the online version of this paper.
